Researchers at The Wistar Institute and the University of South Florida have advanced a novel compound that specifically targets the endoplasmic reticulum (ER) stress response that is frequently hyperactivated in cancer and promotes survival of cancer cells during stressful conditions. The new compound has unique chemical properties that allow for precise activation and can be used for tracking its activity in vivo thanks to the emission of fluorescence.
Research was published online in the Journal of Medicinal Chemistry.
The ER is a cellular structure that oversees protein folding and assembly, and it activates stress response mechanisms in response to the accumulation of misfolded proteins or other stressful conditions, including low oxygen.
“Certain cancers rely on the protective role of the ER stress response to sustain their growth in stressful environmental conditions,” said Chih-Chi Andrew Hu, Ph.D., associate professor in Wistar’s Immunology, Microenvironment & Metastasis Program, and co-lead author on the study with Juan R. Del Valle, Ph.D., from the University of South Florida. “We and other groups showed that genetically and pharmacologically targeting the ER is a very effective way to attack various tumors.”
The Hu lab has been actively advancing a research program for development of compounds to block vital functions of the ER stress response, specifically inhibitors of the IRE1 protein that senses the ER stress and responds by activating a cascade of cellular events. In addition to inducing tumor cell apoptosis, these compounds activate antitumor T-cell function and inhibit tumor-associated immunosuppressive cells in vivo in mouse models, resulting in tumor shrinkage.
“This class of inhibitors has shown therapeutic promise in several cancer types, including chronic lymphocytic leukemia and Burkitt lymphoma,” said Hu. “Therefore, we are very interested in advancing them to the clinic.”
In this study, through a series of chemical modifications, Hu and collaborators created a molecule called PC-D-F07 that is pharmacologically inactive and requires UV irradiation to be “turned on” and converted into the active D-F07, which is a very potent inhibitor of IRE-1 function.
The novel prodrug strategy enhances the efficacy of IRE-1 inhibitors and allows fine control of their activity at a precise time and location by UV irradiation. Importantly, once active, D-F07 emits fluorescence that can be tracked in cells and potentially in vivo, providing a real-time therapy readout. This new strategy for stimulus-mediated release of pharmacological activity provides a promising platform to target the ER stress response for anticancer therapy and for developing other potent inhibitors.
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Biggest Advancement Of Cancer Biomarkers Market Until 2025 Explore By Eminent Players with Analysison October 16, 2019 at 9:03 pm
These biomolecules are called as cancer biomarkers. These biomarkers act as indicators of cancerous processes within the body and are widely used in diagnosis and treatment of cancer. Healthcare ...
- Breast-cancer treatment bills filed in Tallahasseeon October 16, 2019 at 5:15 pm
2009 was a year Jill Weiss will never forget. “I went for a routine mammogram and I knew something was wrong because after the test they made me wait in the room," Weiss said. What came next for the ...
- Hospitals facing shortage of cancer-fighting drug necessary for kids' treatmenton October 16, 2019 at 3:38 pm
ATLANTA — It's an awful situation for families to be in, but it's one some metro Atlanta parents said they're facing: some of their kids fighting cancer here cannot get the treatment they need to ...
- How Obesity Affects Cancer Treatmenton October 16, 2019 at 1:47 pm
discusses the effect of obesity on cancer treatment as well as prevention strategies. As obesity rates hvae climbed in the United States over the past 2 decades, so has the incidence of cancers ...
- 'Each person' cancer should have a personalized plan,' Genomic testing cancer treatment planon October 16, 2019 at 1:25 pm
Many new cancer treatment options have become available over the past few years. But many of these require a comprehensive genomic test first in order to determine which might be beneficial to a ...
- Breast Cancer Treatment and Support for Servicemembers and Their Families Helps Make the Army Strongon October 16, 2019 at 12:53 pm
On Tuesday, though, they were greeted by a blast of pink to support breast cancer awareness and treatment. At the first booth on the right, Leonardo DRS was hosting teammates of the Henry M. Jackson ...
- Scientists harness the power of immune system to test novel cancer treatmenton October 16, 2019 at 11:10 am
Despite its success in treating people with deadly forms of leukemia and lymphoma, there are still many people who do not benefit from the treatment or eventually experience a relapse of their cancer.
- New international exercise guidelines for cancer survivorson October 16, 2019 at 10:49 am
The updated recommendations, published today in Medicine & Science in Sports & Exercise, outline specific 'exercise prescriptions' to address common side effects, such as anxiety and fatigue, ...
- Cancer patients 'should be prescribed exercise' to help with treatment side effectson October 16, 2019 at 6:06 am
Cancer patients should be prescribed exercise to help them cope with treatment side effects, experts have said. A global panel reviewed evidence and then gave guidance about the benefits of working ...
- Lilly's pancreatic cancer treatment fails late-stage studyon October 16, 2019 at 4:21 am
(Reuters) - Eli Lilly and Co said on Wednesday its experimental pancreatic cancer treatment in combination with a cocktail of chemotherapies did not meet the main goal in a late-stage study. The trial ...
via Bing News